Literature DB >> 2868812

Myocardial protection during transient coronary artery occlusion in man: beneficial effects of regional beta-adrenergic blockade.

A Zalewski, S Goldberg, J P Dervan, S Slysh, P R Maroko.   

Abstract

The goal of this study was to verify whether myocardial protection could be achieved via the intracoronary administration of propranolol in patients undergoing percutaneous transluminal coronary angioplasty (PTCA). Accordingly, 21 patients undergoing PTCA were randomly assigned to receive either intracoronary placebo (group A, n = 10) or intracoronary propranolol (group B, n = 11). Three balloon inflations (i.e., coronary artery occlusions) were performed in each patient. Inflations I and II (maximum duration 60 sec) served as control occlusions. Inflation III (maximum duration 120 sec) was performed either after intracoronary administration of saline (2 ml) or propranolol (1.1 +/- 0.2 mg). The following electrocardiographic index of myocardial ischemic injury were measured: (1) time to development of ST segment elevation equal to 0.1 mV and (2) magnitude of ST segment elevation after 60 sec of coronary artery occlusion. Both indexes did not differ significantly between the groups during inflations I and II. In group A the time to development of ST segment elevation of 0.1 mV remained unchanged between the second and third occlusions (25 +/- 5 and 26 +/- 4 sec during inflations II and III, respectively). In group B subselective injection of propranolol into the affected coronary artery significantly prolonged the time to ST segment elevation of 0.1 mV from 19 +/- 4 sec (inflation II) to 53 +/- 9 sec (inflation III; p less than .001). Administration of placebo did not change the magnitude of ST segment elevation 60 sec after coronary artery occlusion between the second and third occlusion in group A (0.16 +/- 0.02 and 0.18 +/- 0.03 mV, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2868812     DOI: 10.1161/01.cir.73.4.734

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  The effects of trapidil and propranolol on platelet aggregation and prostacyclin-thromboxane balance following acute myocardial infarction in rabbits.

Authors:  X A Lu; H Ling; C R Dong; J P Ouyang
Journal:  J Tongji Med Univ       Date:  1988

2.  Similar antiischemic effects of intracoronary atenolol and nifedipine during brief coronary occlusions in humans.

Authors:  S Ghio; S De Servi; L Angoli; E Bramucci; E Eleuteri; S Raffaghello; G Specchia
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

3.  Effect of gallopamil on myocardial ischaemia during percutaneous transluminal coronary angioplasty.

Authors:  B Rauch; J Neumann; G Richardt; R Kranzhöfer; R Barth; R Zimmermann; H P Koch; H Tillmanns; A Schömig
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Local beta-adrenergic blockade does not reduce infarct size after coronary occlusion and reperfusion: a study of coronary venous retroinfusion of metoprolol.

Authors:  S Kobayashi; H Tadokoro; L Rydén; P O Sjöquist; R V Haendchen; E Corday
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

5.  Absence of beneficial effect of intravenous metoprolol given during angioplasty in patients with single-vessel coronary artery disease.

Authors:  J W de Jong; J J Bonnier; T Huizer; R Ciampricotti; J R Roelandt
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

6.  Comparative study on the enhancement of ischemic tolerance by intracoronary pretreatment with three calcium antagonists in pig hearts.

Authors:  H H Klein; S Pich; S Lindert; K Nebendahl; H Kreuzer
Journal:  Cardiovasc Drugs Ther       Date:  1989-01       Impact factor: 3.727

7.  Systemic air embolism after percutaneous computed tomography-guided lung biopsy due to a kink in the coaxial biopsy system: a case report.

Authors:  Hsu-Chao Chang; Mei-Chen Yang
Journal:  BMC Med Imaging       Date:  2018-01-27       Impact factor: 1.930

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.